Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer

International Journal of Colorectal Disease

Volumn 27, Issue 5, 2012, Pages 623-634

  Chirila, Costel ^a   Odom, Dawn ^a   Devercelli, Giovanna ^b   Khan, Shahnaz ^a   Sherif, Bintu N ^a   Kaye, James A ^a   Molnár, István ^c   Sherrill, Beth ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

^c Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

Meta analysis; Metastatic colorectal cancer; Overall survival; Progression free survival; Surrogate endpoint

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; INTERFERON; IRINOTECAN; LEVAMISOLE; MITOMYCIN; OCTREOTIDE; OXALIPLATIN; PANITUMUMAB; TEGAFUR; URACIL;

COLORECTAL CANCER; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG MEGADOSE; HUMAN; META ANALYSIS; METASTASIS; OVERALL SURVIVAL; PERFORMANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VALIDATION STUDY;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM METASTASIS; ROC CURVE; SURVIVAL ANALYSIS;

EID: 84862986717     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-011-1349-7     Document Type: Review

References (24)

1. Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411
2. Fleming TR, Rothmann MD, Lu HL (2009) Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 27:2874-2880
3. Saad ED, Katz A, Hoff PM, Buyse M (2010) Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 21:7-12
4. Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8:431-440
5. Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167-178
6. Buyse M, Molenberghs G (1998) Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014-1029
7. Shi Q, Sargent D (2009) Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol 14:102-111
8. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49-67
9. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M (2001) Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91:2033-2038
10. Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562-4568
11. Buyse M, Burzykowsky T, Caroll K et al (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218-5224
12. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P (2000) Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356:373-378
13. Johnson KR, Ringland C, Stokes BJ et al (2006) Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 7:741-746
14. Sargent DJ, Wieand HS, Haller DG et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670
15. Sherrill B, Amonkar M, Wu Y et al (2008) Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 99:1572-1578
16. Higgins JPT, Green S (eds) (2005) Cochrane handbook for systematic reviews of interventions 4.2.5. In: The Cochrane Library, Issue 3. Wiley, Chichester
17. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
18. Underhill C, Goldstein D, Gorbounova VA et al (2007) A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. Oncology 73:9-20
19. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
20. Hecht JR, Mitchell E, Chidiac T et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for meta-static colorectal cancer. J Clin Oncol 27:672-680
21. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786
22. Kemeny N, Garay CA, Gurtler J et al (2004) Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22:4753-4761
23. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3:32-35
24. Tsujino K, Kawaguchi T, Kubo A et al (2009) Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 4:994-1001